Blue Shield of California has designated UDENYCA®, the reference product, and pegfilgrastim-bmez as preferred pegfilgrastims covered under the Commercial Medical Benefit.
September 2020
Independent Health Medicare Policies has updated UDENYCA® to be the Preferred Agent with the reference product
August 2020
Select Health has updated UDENYCA® to be the Preferred Agent with pegfilgrastim-jmdb
Short Term Recommendations from NCCN Guidelines® & ASCO® Regarding use of Hematopoietic Growth Factors during COVID-19 Pandemic*
Due to COVID-19 pandemic, the short-term recommendations from the NCCN Guidelines® and ASCO® have lowered the threshold for the use of myeloid growth factors from those chemotherapy regimens which have a 20% or higher risk of febrile neutropenia to now include those regimens with a risk of 10-20%, which includes all of the intermediate risk chemotherapy regimens.